Sorry, this entry is only available in Ukrainian.
MHRA схвалила безін’єкційний препарат для невідкладної терапії алергічних реакцій
Вас может заинтересовать:
WEB only
The EMA has launched a consultation on the circumstances in which single-arm trials (SATs) – those without a control group – can be used to support marketing applications for medicines…
WEB only
The life science group Sartorius and Repligen Corporation today announced the launch of an integrated bioreactor system that incorporates Repligen XCell® ATF upstream intensification technology into Sartorius’ Biostat STR® bioreactor, simplifying intensified…
